- Previous Close
49.20 - Open
49.00 - Bid 51.20 x --
- Ask 52.60 x --
- Day's Range
49.00 - 49.00 - 52 Week Range
10.20 - 67.50 - Volume
323 - Avg. Volume
272 - Market Cap (intraday)
6.882B - Beta (5Y Monthly) 0.16
- PE Ratio (TTM)
-- - EPS (TTM)
-1.90 - Earnings Date Apr 29, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
www.veronapharma.comRecent News: I9SA.F
View MorePerformance Overview: I9SA.F
Trailing total returns as of 4/20/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: I9SA.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: I9SA.F
View MoreValuation Measures
Market Cap
4.17B
Enterprise Value
3.92B
Trailing P/E
--
Forward P/E
370.37
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
107.69
Price/Book (mrq)
23.21
Enterprise Value/Revenue
105.73
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.13%
Return on Equity (ttm)
-76.42%
Revenue (ttm)
42.28M
Net Income Avi to Common (ttm)
-173.42M
Diluted EPS (ttm)
-1.90
Balance Sheet and Cash Flow
Total Cash (mrq)
399.76M
Total Debt/Equity (mrq)
111.86%
Levered Free Cash Flow (ttm)
-68.93M